New IFFIm vaccine bonds issued to support life-saving immunisation in poorest countries
- Press Releases
- New IFFIm vaccine bonds issued to support life-saving immunisation in poorest countries
New IFFIm vaccine bonds issued to support life-saving immunisation in poorest countries
28 September 2011
J.P. Morgan, the World Bank and the International Finance Facility for Immunisation ("IFFIm") today announced the issuance of US$ 169.4 million (equivalent) of IFFIm "Vaccine Bonds" in Japan. [日本語]
Bonds will support GAVI Alliance vaccine programmes
Tokyo, 29 September 2011 - J.P. Morgan, the World Bank and the International Finance Facility for Immunisation ("IFFIm") (rated AAA/Aaa/AAA), today announced the issuance of US$ 169.4 million (equivalent) of IFFIm "vaccine bonds" in Japan.
"It's great that a financial transaction provides such a direct link to making a positive contribution to the world. This offering demonstrates Japanese retail investors' continued support for IFFIm and its life-saving purpose". said Christopher Harvey, President and CEO, JPMorgan Securities Japan
Bolster GAVI vaccination programmes
The proceeds will bolster the GAVI Alliance's critical vaccination programmes for children in the world's poorest countries. In the past decade, GAVI (formerly the Global Alliance for Vaccines and Immunisation) has vaccinated more than 288 million people and helped save more than 5 million lives. IFFIm has played a critical role, issuing nearly US$ 3.6 billion of bonds since 2006.
The new transaction includes tranches in three currencies:
- A 5-year South African rand tranche in the amount of ZAR 650 million (US$ 91 million equivalent);
- A 3-year Brazilian real tranche in the amount of BRL 105 million (US$ 66 million equivalent);
- A 4-year Australian dollar tranche in the amount of AUD 12 million (US$ 12.4 million equivalent).
Japanese people commitment to GAVI
"The investment by the Japanese people in IFFIm is a testament to their commitment to GAVI's life-saving work," says Alan Gillespie, IFFIm Board Chair. "We also greatly appreciate J.P. Morgan and our three Japanese distributors for their role in placing IFFIm's AAA-rated bonds."
"We are very grateful for all the work done by J.P. Morgan, Fukuoka Bank, Maeda Securities, Okasan Securities and SMBC Friend Securities," says Doris Herrera-Pol, Director and Global Head of Capital Markets at the World Bank, IFFIm's treasury manager. "Their efforts on behalf of IFFIm will make a real difference in the lives of millions of children in many of the poorest countries in the world."
This issue is IFFIm's first in the Japanese bond market since the Japanese government made its first-ever pledge to GAVI in June this year.
"J.P. Morgan is honoured to work on such an important endeavour," said Christopher Harvey, President and CEO of JPMorgan Securities Japan. "It's great that a financial transaction provides such a direct link to making a positive contribution to the world. This offering demonstrates Japanese retail investors' continued support for IFFIm and its life-saving purpose."
J.P. Morgan's role
J.P. Morgan's role as the underwriter of this transaction expands upon its growing involvement in raising funds for immunisation, including its participation in the GAVI Matching Fund for Immunisation to which its UK office has donated £1.5 million (US$ 2.4 million).
The securities referred to in this document have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under the securities legislation of any state of the United States, and may not be offered or sold in the United States, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. IFFIm does not presently intend to make a public offer of securities in the United States or to register any securities under the Securities Act. Any offering of securities will made by means of a prospectus that may be obtained from IFFIm and will contain detailed information about IFFIm and management as well as financial statements. The securities referred to in this document will only be offered or sold outside the United States in offshore transactions in reliance on Regulation S under the Securities Act.
Summary terms:
For the 5-year ZAR tranche:
Settlement date: | 29 September 2011 |
Principle amount: | ZAR 650 million |
Maturity date: | 29 September 2016 |
Listing: | Luxembourg |
Coupon: | ZAR 6.1% |
ISIN: | XS0668161416 |
For the 3-year BRL Tranche:
Settlement date: | 28 September 2011 |
Principle amount: | BRL 105 million |
Maturity date: | 29 September 2014 |
Listing: | Luxembourg |
Coupon: | BRL: 6.0% |
ISIN: | XS0667610371 |
For the four year AUD Tranche:
Settlement date: | 29 September 2011 |
Principle amount: | AUD 12 million |
Maturity date: | 30 September 2015 |
Listing: | Luxembourg |
Coupon: | AUD 3.4% |
ISIN: | XS0669206665 |
About the GAVI Alliance
The GAVI Alliance is a public-private partnership that aims to immunise children and strengthen health systems in the world's poorest countries. It brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, NGOs, the Bill & Melinda Gates Foundation and private philanthropists. GAVI provides vaccines against diphtheria, tetanus, pertussis combined with haemophilus influenzae type b and hepatitis B as so-called pentavalent (five antigens in one vaccine) as well as vaccines against measles, yellow fever, pneumococcal diseases (pneumonia and meningitis) and rotavirus (diarrhoea).
About IFFIm
International Finance Facility for Immunisation Company (IFFIm) is a multilateral development institution created to accelerate the availability of predictable, long-term funds for health and immunisation programmes through the GAVI Alliance (formerly the Global Alliance for Vaccines and Immunisation) in 70 of the poorest countries around the world. IFFIm was created as a development financing tool to help the international community achieve the Millennium Development Goals. IFFIm's financial base consists of legally binding grants payments from its sovereign sponsors (France, Italy, Norway, South Africa, Spain, Sweden and the UK), on the basis of which IFFIm's is rated AAA/Aaa/AAA (Fitch/Moody's/S&P). The World Bank is the Treasury Manager for IFFIm. IFFIm was established as a charity with the Charity Commission for England and Wales and is registered in England and Wales as a company limited by guarantee with number 5857343 and as a charity with number 1115413.
About the World Bank
The World Bank is a global development cooperative owned by 187 member countries. Its purpose is to help its members achieve equitable and sustainable economic growth in their national economies and to find effective solutions to pressing regional and global problems in economic development and environmental sustainability. The goal is to help overcome poverty and improve standards of living for people worldwide. The International Bank for Reconstruction and Development (IBRD), rated Aaa/AAA (Moody's/S&P), is the oldest and largest entity in the World Bank Group and provides funding, risk management tools and credit enhancement to sovereigns. To fund this activity, IBRD has been issuing debt securities in the international capital markets for 60 years. The World Bank is also the Treasury Manager for IFFIm. In that capacity, the World Bank, as IFFIm's agent, manages IFFIm's finances according to prudent policies and standards. This includes IFFIm's funding strategy and its implementation in the capital markets, rating agency and investor outreach, hedging transactions and investment management. The World Bank also coordinates with IFFIm's donors and manages their pledges and payments as well as IFFIm's disbursements for immunisation and health programmes through the GAVI Alliance.
About J.P. Morgan
JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $2.2 trillion and operations in more than 60 countries. The firm is a leader in investment banking, financial services for consumers, small-business and commercial banking, financial transaction processing, asset management and private equity. A component of the Dow Jones Industrial Average, JPMorgan Chase & Co. serves millions of consumers in the United States and many of the world’s most prominent corporate, institutional and government clients under its J.P. Morgan and Chase brands.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
Reflections on IFFIm: an interview with Rachel Turner
14 November 2024